Search Results
Sep 03, 2026, 07:15 ET ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New
More news about: ADC Therapeutics SA
Aug 25, 2026, 08:30 ET Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
placebo at week 16 including ≥ 4-point reduction in Daily Life Quality Index (DLQI) (72% vs. 54%), ≥ 5-point reduction in Atopic Dermatitis Control Tool (ADCT) (67% vs. 35%), ≥ 4-point reduction in Pain Numeric Rating (Pain NRS) (45% vs. 22%) and ≥ 1.25-point reduction in Atopic Dermatitis Sleep Scale (ADSS)
More news about: Nektar Therapeutics
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational updates.
More news about: ADC Therapeutics SA
Aug 06, 2026, 07:30 ET ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and
More news about: ADC Therapeutics SA
Jul 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of
More news about: ADC Therapeutics SA
Jun 30, 2026, 07:15 ET ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7
More news about: ADC Therapeutics SA
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jun 24, 2026, 07:30 ET ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources
More news about: ADC Therapeutics SA
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination
More news about: ADC Therapeutics SA
May 04, 2026, 07:30 ET ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
EDTLAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter
More news about: ADC Therapeutics SA
May 01, 2026, 04:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options
More news about: ADC Therapeutics SA
Apr 27, 2026, 07:30 ET ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and
More news about: ADC Therapeutics SA
Apr 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of
More news about: ADC Therapeutics SA
Mar 10, 2026, 07:30 ET ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter
More news about: ADC Therapeutics SA
Mar 03, 2026, 07:15 ET ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and
More news about: ADC Therapeutics SA
Mar 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options
More news about: ADC Therapeutics SA
Feb 24, 2026, 07:15 ET ADC Therapeutics to Participate in March Investor Conferences
LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in upcoming investor conferences
More news about: ADC Therapeutics SA
Feb 23, 2026, 07:15 ET ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment
More news about: ADC Therapeutics SA
Feb 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options
More news about: ADC Therapeutics SA
Jan 30, 2026, 10:36 ET $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
focus toward Oncolytics Biotech Inc. (NASDAQ: ONCY), AbbVie (NYSE: ABBV), Genmab (NASDAQ: GMAB), ADC Therapeutics (NYSE: ADCT), and Greenwich LifeSciences (NASDAQ: GLSI).
More news about: Equity Insider
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 08, 2026, 16:05 ET ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from
More news about: ADC Therapeutics SA